Table 4 Relative risk for symptomatic and asymptomatic cholelithiasis in GLP1-RAs groups versus control group
Event | Liraglutide | Dulaglutide | Semaglutide | ||||||
|---|---|---|---|---|---|---|---|---|---|
RR | NNT (harm) | p-value | RR | NNT (harm) | p-value | RR | NNT (harm) | p-value | |
Cholelithiasis | 1.2 | 17.25 | .419 | 1.3 | 14.69 | .334 | 1.4 | 10.96 | .208 |
Symptomatic cholelithiasis | 1.6 | 3.14 | .030* | 0.9 | 16.67 | .674 | 1.4 | 5.56 | .211 |